Medicines: Gantenerumab

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Geoff Kerchner, MD, PhD: Gantenerumab as Disease-Modifying Treatment in Early Alzheimer Disease

Gantenerumab in Early Alzheimer’s Disease | NEJM

Experimental therapy gantenerumab fails to slow or improve Alzheimer's memory loss in clinical

Gantenerumab data presented at CTAD- ADDF statement

Medical Dialogues

Safety results of the Phase III gantenerumab GRADUATE I and II studies

Alzheimer's clinical trial drug yields negative result

Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Second generation of anti-amyloid monoclonal antibodies for Alzheimer's disease

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab Part 1

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab

Important developments in dementia: biomarkers & clinical trials

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab Part 3

Conversations Episode 2 - Building on Amyloid Lowering

Cognition Therapeutics, Inc.

Effective Treatments and Prevention of Alzheimer’s Disease: The Time is Now - Research on Aging

University of California Television (UCTV)

Advances in Alzheimer's disease biomarkers & therapies

Why Enhancing Metabolic Health Could be the Key to Preventing Alzheimer's Disease

DavidPerlmutterMD